KTE-X19 Proves Comparable to Current Therapies in Treating High-Risk MCL

When compared to currently approved therapies, KTE-X19 demonstrated comparable pharmacologic and clinical outcomes in patients with high-risk MCL characteristics versus lower-risk characteristics defined by tumor protein TP53 mutation or high Ki-67 proliferation index.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news